Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases.
about
Insights into atomic-level interaction between mefenamic acid and eudragit EPO in a supersaturated solution by high-resolution magic-angle spinning NMR spectroscopy.Mechanistic insight into the dramatic improvement of probucol dissolution in neutral solutions by solid dispersion in Eudragit E PO with saccharin.Parallel thermal analysis technology using an infrared camera for high-throughput evaluation of active pharmaceutical ingredients: a case study of melting point determination.Theory and practice of supersaturatable formulations for poorly soluble drugs.Acoustic levitation: recent developments and emerging opportunities in biomaterials research.Media-dependent morphology of supramolecular aggregates of β-cyclodextrin-grafted chitosan and insulin through multivalent interactions
P2860
Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current status of amorphous fo ...... ons for early clinical phases.
@en
Current status of amorphous fo ...... ons for early clinical phases.
@nl
type
label
Current status of amorphous fo ...... ons for early clinical phases.
@en
Current status of amorphous fo ...... ons for early clinical phases.
@nl
prefLabel
Current status of amorphous fo ...... ons for early clinical phases.
@en
Current status of amorphous fo ...... ons for early clinical phases.
@nl
P356
P1476
Current status of amorphous fo ...... ions for early clinical phases
@en
P2093
Kohsaku Kawakami
P304
P356
10.1002/JPS.21816
P407
P577
2009-09-01T00:00:00Z